Ken Griffin Lucid Diagnostics Inc. Transaction History

Citadel Advisors LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$0.81 - $1.52 $273 - $513	-338 Reduced 1.14%	29,301 $23,000
Q4 2023 Feb 14, 2024	SELL	$1.16 - $1.54 $7,813 - $10,373	-6,736 Reduced 18.52%	29,639 $41,000
Q3 2023 Nov 14, 2023	SELL	$1.17 - $1.65 $30,579 - $43,124	-26,136 Reduced 41.81%	36,375 $42,000
Q2 2023 Aug 14, 2023	BUY	$1.28 - $1.78 $80,014 - $111,269	62,511 New	62,511 $86,000
Q3 2022 Nov 14, 2022	BUY	$1.53 - $3.45 $6,894 - $15,545	4,506 Added 14.62%	35,333 $54,000

2.54M

Ticker LUCD
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 38,568,500
Market Cap $29.3M
Description
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarc...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.